HealWELL AI Inc

HEALWELL acquires Toronto-based Mutuo Health Solutions! View details here.

HEALWELL AI Closes Upsized $20 Million Bought Deal Offering

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, ONTARIO, May 22, 2024 – HEALWELL AI INC. (“HEALWELL” or the “Company”) (TSX: AIDX) is pleased to announce today that it has closed its previously announced “bought deal” private placement offering and issued 14,815,000 units of the Company (the “Units”) at a price of $1.35 per Unit, for aggregate gross proceeds of $20,000,250 (the “Offering”).

Dr. Alexander Dobranowski, CEO of HEALWELL commented, “In addition to strengthening the Company’s balance sheet, the completion of the Offering positions the Company well to carry out the remainder of its 2024 growth initiatives. This milestone marks not just a financial achievement but a significant step towards realizing our mission to improve healthcare and save lives through the early identification and detection of disease.”

Each Unit is comprised of one Class A subordinate voting share of the Company (a “Share”) and one-half of one Share purchase warrant (each whole warrant, a “Warrant”) of the Company. Each Warrant entitles the holder thereof to purchase one additional Share at an exercise price of $1.80 for a period of two (2) years following the closing of the Offering.

The Offering was conducted on a “bought deal” basis by Clarus Securities Inc. and Eight Capital, as co-lead underwriters, together with Beacon Securities Limited, Canaccord Genuity Corp., Stifel Nicolaus Canada Inc., Ventum Financial Corp., Cormark Securities Inc., Raymond James Ltd. and Maxim Group LLC, as underwriters (collectively, the “Underwriters”).

In connection with the Offering, the Underwriters received a cash commission equal to 6.0% of the gross proceeds of the Offering (the “Cash Commission”) and that number of non-transferable broker warrants (the “Broker Warrants”) as is equal to 6.0% of the aggregate number of Units sold under the Offering. Each Broker Warrant is exercisable to acquire one Share at a price of $1.35 per Share for a period two (2) years after the closing of the Offering. Each of the Cash Commission paid and Brokers Warrants issued to the Underwriters was reduced to 3% with respect to subscribers identified on the Company’s president’s list, which president’s list was in the amount of $13,600,035.

The Company intends to use the net proceeds of the Offering for growth initiatives and general corporate and working capital purposes. All securities issued pursuant to the Offering are subject to a four-month and one day hold period from the closing date of the Offering in accordance with applicable securities legislation.

 

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful. No securities may be offered or sold to, or for the account or benefit of persons in the United States or to any U.S. persons or in any other jurisdiction in which such offer or sale would be unlawful absent registration under the U.S. Securities Act, and any applicable state securities laws or an exemption therefrom or qualification under the securities laws of such other jurisdiction or an exemption therefrom. “United States” and “U.S. persons” shall have the meaning given to them in Regulation S under the U.S. Securities Act.

About HEALWELL AI Inc.

HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company’s road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit: healwell.ai/

Contact Information

Alexander Dobranowski
Chief Executive Officer
416-440-4040 x.201
ir@healwell.ai

Cautionary Note Regarding Forward-Looking Information

Certain statements in this press release constitute “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements in this press release include statements with respect to, among others, the Company’s business strategy, plans and other expectations, beliefs, goals, objectives, and information and statements about possible future events, including the intended use of proceeds of the Offering and final approval of the Toronto Stock Exchange and any other regulatory approvals with respect to the Offering. Forward-looking statements are often, but not always, identified by words or phrases such as “expects”, “is expected”, “anticipates”, “believes”, “plans”, “projects”, “estimates”, “assumes”, “intends”, “strategies”, “targets”, “goals”, “mission”, “forecasts”, “objectives”, “budgets”, “schedules”, “potential” or variations thereof or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions. Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by the Company as of the date of such statements, are outside of the Company’s control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-looking statements contained in this press release are based on various assumptions and factors, including, but not limited to, the following: the assumption that the Toronto Stock Exchange will provide final approve the Offering and that the risk factors noted below, collectively, do not have a material impact on the Company’s business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

Known and unknown risk factors, many of which are beyond the control of the Company, could cause the actual results of the Company to differ materially from the results, performance, achievements or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled “Risk Factors” in the Company’s most recent annual information form which is available under the Company’s SEDAR+ profile at www.sedarplus.com. The risk factors are not intended to represent a complete list of the factors that could affect the Company and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.

Khure Health

Khure Health is a wholly owned subsidiary of HEALWELL AI. Khure is an AI health technology company whose precision medicine platform harnesses clinical data, enabling physicians to rapidly screen and identify patients with rare diseases and facilitate more personalized treatment.

Khure is actively working with and/or has rare and specialty disease programs in development with 6 of the top 10 pharma companies and international disease associations.
Visit Website →

This will close in 0 seconds

Pentavere

HEALWELL AI is a majority shareholder of Pentavere Research Group, a globally recognized and award-winning AI digital health company that has built a best-in-class AI engine to identify patients that are eligible for approved medications or interventions, to improve outcomes for patients and help drive therapy growth and penetration. Over the past several years, Pentavere has published an impressive array of literature in high-impact, peer-reviewed medical journals, totaling more than 30 manuscripts, which serve as a testament to Pentavere’s capabilities and adds significant credibility to their technology.
Visit Website →

This will close in 0 seconds

Intrahealth

Intrahealth is a pioneering force in healthcare technology, specializing in the development and implementation of state-of-the-art EMR solutions. With a relentless commitment to advancing patient care, Intrahealth empowers healthcare providers, institutions, and governments with innovative digital tools designed to enhance healthcare delivery and improve patient outcomes.
Visit Website →

This will close in 0 seconds

VeroSource Solutions

VeroSource Solutions is a digital health company established in 2014 to empower people and unlock the potential in Canadian healthcare. Its team of professionals has extensive experience in the full lifecycle of healthcare IT solutions and offers healthcare providers the technology and support needed to go digital. VeroSource’s cloud-first multi-channel software securely connects people, data and systems to drive digital healthcare transformation. Founded in Fredericton, NB, VeroSource has grown to include team members across Ontario and Atlantic Canadian.
Visit Website →

This will close in 0 seconds

BioPharma Services

BioPharma Services is a leading contract research organization (CRO) based in Toronto, Canada, specializing in Phase 1 and Phase 2a clinical trials. With a focus on scientific integrity, operational excellence, and adaptive processes tailored to each client’s needs, BioPharma Services has established a reputation for delivering high-quality results in the pharmaceutical and biotech industries. BioPharma’s comprehensive services also include Bioanalysis at their GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis (CDISC), Data Management and Medical Writing.
Visit Website →

This will close in 0 seconds

PolyClinic

HEALWELL AI Polyclinic provides onsite integrated health services including primary care, specialist care, lab services, and an in-house clinical research organization. With integrated systems and data-driven tools, HEALWELL AI Polyclinic plans to unlock meaningful insights from consistent, high-quality, structured clinical information from over 50 primary care physicians and specialists, labs, and clinical trials.
Visit Website →

This will close in 0 seconds

Doctorly

Founded in 2018, doctorly is a European based digital health-tech startup with a company mission of 'enabling people to live healthier lives'. With an initial focus on Europe’s largest market, Germany, doctorly has built a brand new, fully regulated practice management software to redefine how medical practices work. As an all-in-one solution, doctorly provides a fully centralised, cloud powered, GDPR compliant, medical practice operating system that dramatically reduces the time and effort doctors and medical assistants spend on day-to-day administrative tasks. doctorly is financially backed by some of the world’s most renowned venture capital firms. To learn more about doctorly please visit: www.doctorly.de

Read the original press release here.
Visit Website →

This will close in 0 seconds

xAI

xAI is a company working on building artificial intelligence to accelerate human scientific discovery. They're guided by their mission to advance our collective understanding of the universe. The team is led by Elon Musk, CEO of Tesla and SpaceX. Collectively their team has contributed some of the most widely used methods in the field, in particular the Adam optimizer, Batch Normalization, Layer Normalization, and the discovery of adversarial examples. They further introduced innovative techniques and analyses such as Transformer-XL, Autoformalization, the Memorizing Transformer, Batch Size Scaling, μTransfer, and SimCLR. They have worked on and led the development of some of the largest breakthroughs in the field including AlphaStar, AlphaCode, Inception, Minerva, GPT-3.5, and GPT-4. Learn more at https://x.ai/ Read the original press release here.
Visit Website →

This will close in 0 seconds

Mutuo Health Solutions

Mutuo Health Solutions is a Toronto-based medical artificial intelligence company focused on developing predictive clinical AI technology. Their flagship product, AutoScribe, is an advanced AI-powered ambient scribe solution that transcribes clinician-patient interactions into high-quality electronic medical records in real time. AutoScribe utilizes natural language processing and machine learning technology to accurately capture and structure patient data, enabling healthcare providers to focus on patient care and improve clinical efficiency.

Visit Website →

This will close in 0 seconds

Abstractive Health

Abstractive Health is on a mission to transform the healthcare industry by automating clinical documentation with generative AI. Their innovative AI software creates comprehensive patient summaries, streamlining workflows and empowering healthcare providers to focus on patient care. By harnessing advanced language models, the company delivers accurate, medically relevant insights directly to clinicians, enabling informed decision-making and improved patient outcomes. Read the original press release here. 

Visit Website →

This will close in 0 seconds